Research area: Stability of lyophilised antibody drugs
Research sponsor: BBSRC/ NIBSC
Antibody-based biologics such as monoclonal antibodies are the fastest growing segments in the biopharmaceutical industry due to their unique therapeutic potential. The challenges to formulate these new therapeutics economically and effectively for safe delivery to patients are greater than ever. In order to overcome these challenges, most biologics are lyophilised (freeze-dried) but physical or chemical degradation may still occur in process or during storage causing major financial loss.
I am currently working on a collaborative project between the Surface and Particle Engineering Laboratory (department of Chemical engineering, Imperial) and The National Institute for Biological Standards and Control (NIBSC) to characterise different lyophilised formulations.